Vaccine: X最新文献

{"title":"A mixed methods study protocol for CONFIVAC, an intervention to enhance paediatric nurses' and paediatricians' skills to promote vaccination and vaccine confidence","authors":"Elisabet Henderson ,&nbsp;Sara Valmayor ,&nbsp;Victoria Porthé ,&nbsp;Alba Asensio ,&nbsp;Xavier Bruna ,&nbsp;Usue Elizondo-Alzola ,&nbsp;Anna Ramirez-Morros ,&nbsp;Gemma Ricós ,&nbsp;Josep Vidal-Alaball ,&nbsp;M. Isabel Pasarín ,&nbsp;Cristina Rius ,&nbsp;Elena Roel ,&nbsp;Elia Díez ,&nbsp;CONFIVAC Research Group","doi":"10.1016/j.jvacx.2025.100635","DOIUrl":"10.1016/j.jvacx.2025.100635","url":null,"abstract":"<div><h3>Background</h3><div>Vaccine hesitancy (VH), defined as the delay in acceptance or refusal of vaccination despite its availability, is a global health threat. Paediatric healthcare workers (PHCWs) are key in promoting vaccination but often feel unprepared to manage VH effectively. We developed CONFIVAC, an intervention designed to strengthen the knowledge, self-efficacy, and skills of PHCWs in improving childhood vaccination, addressing VH, and fostering a culture of immunization within primary care. This study protocol outlines the design, contents, planned implementation, and mixed-methods effectiveness evaluation of CONFIVAC.</div></div><div><h3>Methods</h3><div>We will conduct a two-arm parallel cluster randomised controlled trial including PHCWs from 74 paediatric primary healthcare teams from Catalonia, Spain. Paediatric teams will be randomly assigned to the intervention or control arm (standard care). PHCWs in the intervention arm will participate in the training program CONFIVAC, which includes 10 h of online learning and 2 h of in-person training featuring role-playing exercises. Grounded in health behaviour theories, the curriculum includes evidence-based strategies to improve vaccination uptake. It addresses key topics such as vaccine knowledge, communication strategies, and organizational tools to promote vaccination. Process evaluation will assess overall satisfaction, likelihood of recommending CONFIVAC, and applicability. Main effectiveness outcomes will include vaccine-promoting behaviours (presumptive communication, anticipation of upcoming vaccines, and explicitly recommending vaccination in VH cases) and self-perception of having sufficient training to handle VH. We will perform adjusted ordinal regression models using an intention-to-treat approach. Quantitative results will be triangulated with qualitative insights from focus groups of PHCWs in the intervention arm employing a phenomenological approach.</div></div><div><h3>Discussion</h3><div>CONFIVAC is expected to provide PHCWs with evidence-based knowledge, communication techniques, and organizational skills to address VH and promote vaccination. By enhancing their skills and confidence, we aim to improve vaccination uptake and streamline vaccine-related tasks in primary care settings.</div><div><strong>Trial registration:</strong> ClinicalTrials ID: <span><span>NCT06489236</span><svg><path></path></svg></span></div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"24 ","pages":"Article 100635"},"PeriodicalIF":2.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring a promising vaccine candidate against Leishmania major: Insights from Gp63, LACK, TSA, LmSTI1and KMP11 antigens in BALB/c mice","authors":"Sama Rashidi ,&nbsp;Effat Noori ,&nbsp;Bahram Kazemi ,&nbsp;Seyyed Javad Seyyed Tabaei ,&nbsp;Gholamreza Hatam","doi":"10.1016/j.jvacx.2025.100633","DOIUrl":"10.1016/j.jvacx.2025.100633","url":null,"abstract":"<div><div>Leishmaniasis, a significant health issue in tropical regions, is spreading due to the challenges in treatment and the absence of an effective vaccine. The development of an effective vaccine for <em>Leishmania major</em> is crucial. This study aimed to assess the protective effectiveness of “Leish21,” a DNA vaccine containing multiple epitopes, against cutaneous leishmaniasis caused by <em>L. major</em> in different groups of BALB/c mice. The Leish21 vaccine was successfully transfected into eukaryotic cells, and its expression was confirmed using RT-PCR. Following infection with <em>L. major</em> promastigotes, immunized mice with Leish21 + IL12 and Leish21 showed a significant reduction in lesion diameter compared to the control group. In conclusion, the Leish21 vaccine triggered a Th1 immune response, and the addition of IL12 enhanced its efficacy against <em>L</em>. <em>major</em> infection.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"24 ","pages":"Article 100633"},"PeriodicalIF":2.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current evidence on improving influenza vaccine uptake in low- and middle-income countries: A scoping review of determinants and interventions","authors":"Prima Alam ,&nbsp;Lerato Tsotetsi ,&nbsp;Tshepiso Msibi ,&nbsp;Mulalo Mashamba ,&nbsp;Janan Dietrich","doi":"10.1016/j.jvacx.2025.100634","DOIUrl":"10.1016/j.jvacx.2025.100634","url":null,"abstract":"<div><div>Influenza is a vaccine-preventable disease affecting three to five million individuals across the globe annually. Low- and middle-income countries (LMICs) bear substantial health and economic consequences of influenza-related mortality. Despite this disproportionate burden, influenza vaccinations are seldom used across LMICs. In this article, we reviewed current evidence on improving influenza vaccine uptake within LMICs by examining key determinants and interventions. We conducted a scoping review of peer-reviewed studies pertaining to influenza vaccine uptake in LMICs. We searched five electronic databases for articles published 2014–2024, using terms relating to influenza vaccines, interventions, and context. Twenty-four articles met the inclusion criteria with sample sizes ranging from 38 to 9420. The authors followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines and synthesized the included articles using thematic analysis.</div><div>All studies included in this review were cross-sectional and primarily used quantitative surveys. Most of the included studies were conducted in Sub-Saharan Africa (South Africa, Kenya, Malawi, and Sierra Leone) and the Middle East and North Africa (Tunisia, Jordan, Lebanon, and Egypt). Articles predominantly targeted vulnerable populations including elderly, pregnant women, and young children as well as healthcare workers. Participants across the included studies reported high levels of willingness to receive the influenza vaccination but lower levels of uptake. Having positive perceptions and attitudes towards the efficacy and safety of the vaccine, greater belief in disease susceptibility, physician recommendations, and a history of being vaccinated were associated with greater willingness to receive the influenza vaccine. Six articles explored national campaigns or researcher-led interventions to improve influenza vaccine uptake with educational campaigns positively changing attitudes towards influenza vaccination and integration of year-round vaccination campaigns with routine services as an effective vaccine delivery method.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"24 ","pages":"Article 100634"},"PeriodicalIF":2.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice","authors":"Azzania Fibriani ,&nbsp;Nicholas Yamahoki ,&nbsp;Annisa Meliana Shani ,&nbsp;Afifatur Rofiqoh ,&nbsp;Agust Leo Fany Siregar ,&nbsp;Cynthia Gunawan ,&nbsp;Carola Giovanni Danira Mayorga ,&nbsp;Tommy Octavianus Soetrisno Tjia ,&nbsp;Husna Nugrahapraja ,&nbsp;Ernawati Arifin Giri-Rachman ,&nbsp;Marselina Irasonia Tan","doi":"10.1016/j.jvacx.2025.100632","DOIUrl":"10.1016/j.jvacx.2025.100632","url":null,"abstract":"<div><div>Vaccination is effective to end pandemics, including the Coronavirus disease-2019 (COVID-19). However, the evolution of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) which is characterized by the emergence of the virus variants has a great potential to cause a decrease in the effectiveness of the developed vaccines. One of the vaccine platforms that may overcome vaccine failure due to viral genetic mutations is a multi-epitope vaccine. Using the reverse vaccinology approach, in this study, we developed a multi-epitope peptide-based COVID-19 vaccine composed of immunodominant epitopes. The multi-epitope peptide was designed in silico, successfully expressed in <em>E. coli</em> BL21 (DE3), and purified. Furthermore, the vaccine candidate was proven to induce the production of SARS-CoV-2 antigen-specific IgM and IgG antibodies in BALB/c mice without any considerable adverse reaction. The results also showed that the generated antibodies were reactive to SARS-CoV-2-positive patient nasopharyngeal swab samples containing different circulating Omicron XBB F456L variants. Therefore, our study demonstrates that the multi-epitope peptide has the potential to be further developed as a safe and relevant COVID-19 vaccine. Additionally, this study also demonstrates that reverse vaccinology is useful to facilitate the development of relevant vaccines for emerging infectious diseases.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"24 ","pages":"Article 100632"},"PeriodicalIF":2.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid- and long-term mortality risk factors after COVID-19 hospitalization: A retrospective observational study in Peru","authors":"Max Carlos Ramírez-Soto ,&nbsp;Hugo Arroyo-Hernández","doi":"10.1016/j.jvacx.2025.100631","DOIUrl":"10.1016/j.jvacx.2025.100631","url":null,"abstract":"<div><h3>Background</h3><div>Recent studies have demonstrated the long-term mortality risk in COVID-19 survivors. However, the risk factors for mid- and long-term mortality after COVID-19 hospitalization in the Peruvian population are unknown. We evaluated risk factors associated with mid- and long-term mortality after COVID-19 hospitalization.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study in survivors of SARS-CoV-2 infection discharged from hospital during 2020–2023, using open data from the Ministerio de Salud, Peru. The main outcome measures were mortality among all survivors of SARS-CoV-2 infection at mid-term (61 to 364 days after hospital discharge) and long-term (≥1 year after hospital discharge).</div></div><div><h3>Results</h3><div>Of the 97,249 COVID-19 survivors who were discharged from hospital, 523 patients died within 61 to 364 days of discharge and 219 patients died after 1 year or more since they were discharged. The older age (adjusted ratio hazards [aHR], 3.46; 95 % CI, 2.87–4.17; <em>p</em> &lt; 0.001 to mid-term; and aHR, 3.48; 95 % CI, 2.63–4.61; <em>p</em> &lt; 0.001 to long-term), oxygen support (aHR, 1.64; 95 % CI, 1.30–2.07; <em>p</em> &lt; 0.001 to mid-term), and the hospitalization stay of 4 to 9 days (aHR, 1.54; 95 % CI, 1.18–2.00; <em>p</em> = 0.001 to mid-term; and aHR, 1.64; 95 % CI, 1.04–2.58; <em>p</em> = 0.034 to long-term) and ≥ 10 days (aHR, 2.44; 95 % CI, 1.89–3.17; <em>p</em> &lt; 0.001 to mid-term; and aHR, 2.98; 95 % CI, 1.89–4.68; <em>p</em> &lt; 0.001 to long-term) were associated with increased mortality risk. Compared with the unvaccinated, administration of 1 to 2 or 3 to 4 doses of the SARS-CoV-2 vaccine before or after hospitalization was associated with a reduced risk of death in the mid- and/or long-term.</div></div><div><h3>Conclusion</h3><div>Although older age and longer hospital stay were associated with an increased risk of death after COVID-19 hospitalization in the mid- and long-term, and oxygen support increased the risk of death in the mid-term, vaccination against SARS-CoV-2 reduced the risk of death.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"24 ","pages":"Article 100631"},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study","authors":"Ottavia Prunas ,&nbsp;Andrew Tiu ,&nbsp;Kayoko Shioda ,&nbsp;Shweta Bansal ,&nbsp;Daniel M. Weinberger","doi":"10.1016/j.jvacx.2025.100622","DOIUrl":"10.1016/j.jvacx.2025.100622","url":null,"abstract":"<div><div>The relationship between infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and disease caused by <em>Streptococcus pneumoniae</em> remains uncertain. This case-control study investigated the association between pneumococcal vaccination and the progression to severe outcomes among COVID-19 patients aged 65 and older in the United States. We identified COVID-19 patients aged 65 and older with severe outcomes (cases) and those with non-severe or less severe outcomes (controls) from Medicare data from April 2020 to December 2021. Logistic regression models were employed to evaluate the association between prior receipt of pneumococcal vaccination (13-valent conjugate vaccine [PCV13] and/or 23-valent pneumococcal polysaccharide vaccine [PPSV23]) and severe COVID-19 outcomes. A total of 28,124 COVID-19 patients exhibited severe respiratory symptoms or were admitted to the intensive care unit (ICU). The odds of progression from non-severe symptoms to severe respiratory symptoms were modestly lower among COVID-19 patients with PCV13 receipt (odds ratio (OR): 0.91 (95 % confidence interval [CI], 0.88, 0.93), compared to those without PCV13. The odds of requiring ICU admission were lower among COVID-19 patients with severe respiratory outcomes who received PCV13, compared to those who did not (OR: 0.92; 95 % CI, 0.88, 0.97). The magnitude of the associations was similar when evaluating the associations between the receipt of influenza or zoster vaccinations and the severity of COVID-19 outcomes. Finally, there was no association between receiving PPSV23 more than five years ago and COVID-19 severity. Overall, our findings indicated modest to no association between pneumococcal vaccination and severe COVID-19 outcomes among older adults with COVID-19.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"24 ","pages":"Article 100622"},"PeriodicalIF":2.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143636570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoting influenza vaccination behavior among healthcare workers in the gulf cooperation council countries; Lessons from the [2023 SANOFI Round Table Meeting, September 17th, 2023, Valencia, Spain]","authors":"Gill A. ten Hoor ,&nbsp;Sarah F. Bertrand ,&nbsp;Mathieu Bangert ,&nbsp;Ayman Chit ,&nbsp;Khalid H. Elawad ,&nbsp;Ezzedine Mohsni ,&nbsp;Robert A.C. Ruiter ,&nbsp;Mine D. Tanriover ,&nbsp;Alireza Mafi","doi":"10.1016/j.jvacx.2025.100617","DOIUrl":"10.1016/j.jvacx.2025.100617","url":null,"abstract":"<div><div>Influenza poses a significant health and economic burden globally, with healthcare workers (HCWs) being particularly vulnerable. Despite their critical role in public health, influenza vaccination coverage rates (VCR) among HCWs in the Middle East remain low, with some countries reporting rates as low as 24.7 %. This study aims to identify the factors contributing to low VCR among HCWs and propose solutions to enhance vaccination uptake based on insights from the [redacted] alongside the review of literature to develop targeted interventions. Key strategies include a multifaceted approach, multi-stakeholder accountability, and robust data collection systems. The study emphasizes the need for evidence-based guidelines, streamlined education, and efficient policy frameworks to improve VCR among HCWs in the Middle East. The proposed solutions aim to bridge the gap between knowledge and practice, ensuring a resilient healthcare workforce capable of mitigating influenza outbreaks. The findings underscore the importance of stakeholder engagement and the development of a comprehensive ‘toolbox’ for early implementation in GCC countries, focusing on physicians, nurses/midwives, and pharmacists. This approach aims to foster long-term maintenance and adaptability of vaccination programs, ultimately enhancing public health protection.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"23 ","pages":"Article 100617"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of identity assay for human papillomavirus genotypes using Simple Plex™ microfluidic automated ELISA","authors":"Kyle Esposito,&nbsp;Richard R. Rustandi,&nbsp;Matthew Schombs","doi":"10.1016/j.jvacx.2025.100621","DOIUrl":"10.1016/j.jvacx.2025.100621","url":null,"abstract":"<div><div>The IVRP (In-vitro Relative Potency) assay is a sandwich-type immunoassay used to measure relative potency as well as identity for some vaccine products. However, this traditional enzyme-linked immunosorbent assay (ELISA) method is time consuming due to the labor-intensive hands-on approach especially for multivalent vaccine products such as Human Papillomavirus (HPV). Development of a quick and simple assay for specific and faster identification of all nine genotypes of Gardasil®9 HPV vaccine was evaluated using ProteinSimple's Simple Plex Ella™ technology which can assist in sample transport vial identification and drug product formulation. An analysis of cross-reactivity for each antibody against each HPV genotype was conducted and showed high specificity of the new assay. The technology employed confers the assay's extremely fast analysis turn-around-time in a high throughput atmosphere, the Ella™ is also designed to run each well in triplicate which allows for more samples to be analyzed on an individual plate, while using less reagents than the typical ELISA based assay. The Ella™ also has scalable plates if less or more samples need to be tested, therefore having high potential to replace the manual ELISA identity assay. The instrument operational process is completely automated, including all antibodies, samples additions, as well as all wash steps, enabling result generation in approximately an hour.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"23 ","pages":"Article 100621"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination hesitancy among hemodialysis patients: A mixed-methods study","authors":"Yuka Sugawara ,&nbsp;Masao Iwagami ,&nbsp;Kan Kikuchi ,&nbsp;Toyohiro Hashiba ,&nbsp;Sayaka Yabushita ,&nbsp;Risa Hara ,&nbsp;Toshio Hasegawa ,&nbsp;Iino Yasuhiko ,&nbsp;Masaomi Nangaku","doi":"10.1016/j.jvacx.2025.100623","DOIUrl":"10.1016/j.jvacx.2025.100623","url":null,"abstract":"<div><h3>Background</h3><div>Vaccine hesitancy is a long-standing concept popularized during the coronavirus disease 2019 (COVID-19) pandemic. However, the underlying reasons and factors associated with COVID-19 vaccine hesitancy among hemodialysis patients have not been thoroughly investigated. Thus, here we investigated these issues using a mixed-methods approach.</div></div><div><h3>Methods</h3><div>A questionnaire survey was conducted of 1086 voluntary hemodialysis patients at 36 Japanese facilities. The questionnaire asked about detailed background factors, COVID-19 vaccination status, and reasons for non-vaccination. A multivariate logistic regression analysis was conducted of vaccine hesitancy, and 10 unvaccinated patients were interviewed to further investigate their reasons for non-vaccination.</div></div><div><h3>Results</h3><div>There were 54 (5.0 %) unvaccinated and 1032 (95.0 %) vaccinated participants. In the multivariate analysis, COVID-19 vaccine hesitancy was independently associated with a history of anaphylaxis (adjusted odds ratio [aOR], 4.05; 95 % confidence interval [CI], 1.46–11.21), living with an unvaccinated person (OR, 4.90; 95 % CI, 2.51–9.56), and using X (formerly Twitter) as the main source of information (aOR, 8.58; 95 % CI, 1.86–39.58), whereas those who received an annual influenza vaccination were less likely to show COVID-19 vaccine hesitancy (aOR, 0.19; 95 % CI, 0.1–0.36). The interview findings suggested that other factors associated with non-vaccination were not included in the questionnaire survey, such as missing opportunities to receive the initial vaccination and doctors' suggestions to avoid vaccination.</div></div><div><h3>Conclusions</h3><div>This study combined qualitative and quantitative methods to identify several factors associated with COVID-19 vaccine hesitancy among hemodialysis patients. These results will be useful during future pandemics.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"23 ","pages":"Article 100623"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review”. [Vaccine X, 2024 Feb 23;18:100464]","authors":"Hannah G. Davies ,&nbsp;Emma V. Thorley ,&nbsp;Rossul Al-Bahadili ,&nbsp;Natalina Sutton ,&nbsp;Jessica Burt ,&nbsp;Lauren Hookham ,&nbsp;Kostas Karampatsas ,&nbsp;Philipp Lambach ,&nbsp;Flor Muñoz ,&nbsp;Clare L. Cutland ,&nbsp;Saad Omer ,&nbsp;Kirsty Le Doare","doi":"10.1016/j.jvacx.2025.100612","DOIUrl":"10.1016/j.jvacx.2025.100612","url":null,"abstract":"","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"23 ","pages":"Article 100612"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143591896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}